Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma.

@article{Offidani2006ThalidomideDA,
  title={Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma.},
  author={Massimo Offidani and Laura Corvatta and Maria-Novella Piersantelli and Giuseppe Visani and Francesco Alesiani and Marino Brunori and Piero Galieni and Massimo Catarini and Maurizio Burattini and Riccardo Centurioni and Mario Ferranti and Serena Rupoli and Anna Rita Scortechini and Luciano Giuliodori and Marco Candela and Debora Capelli and Mauro Montanari and Attilio Olivieri and Antonella Poloni and Claudia Polloni and Monica Marconi and Pietro Leoni},
  journal={Blood},
  year={2006},
  volume={108 7},
  pages={2159-64}
}
We present the results of a phase 2 study using thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) in the treatment of 50 patients older than 65 years with newly diagnosed multiple myeloma. Thalidomide 100 mg was administered orally at bedtime continuously, dexamethasone 40 mg was administered orally on days 1 to 4 and 9 to 12, and pegylated liposomal doxorubicin 40 mg/m2 was administered intravenously on day 1 over the 28-day cycle. Response was assessed according to the… CONTINUE READING
26 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 26 extracted citations

Similar Papers

Loading similar papers…